Net loss for of $9.4 million or $0.18 per share Read more…
Where’s the beef? Read more…
Encouraging with the amount of shares sold … Read more…
“Grifting” the CIRM from Cleveland … Read more…
From a high flyer to a low hanger that lives to spend another day … Read more…
From MultiStem after Spinal Cord Injury … Read more…
Cell Therapy Safe and Study Proceeding at High Dose … Read more…
ReNeuron submitted 2 applications to UK regulatory authority to commence multi-site ischemic stroke P2 clinical trial Read more…
Net loss of $3.7M or $0.13 per share Read more…
2 Analysts Evaluation, Ranking and Price Targets articulate a Wide Gap …or
Renewed Optimism and Indications as Executives Buy-in Read more…
Founder and Director of Research, Henry McCusker enters his tenth (10) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.
I started this blog to add commentary, update news flow and insightful opinions that are intelligent, fit to print and SEC compliant.